TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.36% | -30.56% | 28.78% | 42.97% | 57.68% |
| Total Depreciation and Amortization | -20.51% | -15.86% | -6.98% | -0.97% | 9.78% |
| Total Amortization of Deferred Charges | 31.05% | 71.41% | 117.74% | 213.48% | -- |
| Total Other Non-Cash Items | 451.37% | 770.71% | -15.76% | -39.36% | -111.57% |
| Change in Net Operating Assets | 110.25% | 121.66% | 150.14% | 67.41% | -1,113.16% |
| Cash from Operations | 42.01% | 55.90% | 52.08% | 48.53% | 32.32% |
| Capital Expenditure | 70.47% | -166.09% | -38.98% | -30.18% | -59.66% |
| Sale of Property, Plant, and Equipment | 0.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 73.31% | -142.90% | -26.99% | 47.83% | 37.15% |
| Total Debt Issued | -100.00% | -60.00% | -60.00% | -60.00% | -- |
| Total Debt Repaid | 85.71% | 3.57% | -11.49% | -29.89% | -52.87% |
| Issuance of Common Stock | 412.34% | 46.76% | 102.18% | 357.25% | 288.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 41.79% | 20.21% | 20.82% | -106.25% | -108.72% |
| Cash from Financing | 42.62% | -18.91% | -4.30% | -43.50% | -10.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 378.44% | 466.36% | 214.05% | -21.05% | 434.82% |